In GBM, LTF and IL2RA align with immune-evasive and angiogenic programs that are mechanistically plausible mediators of Temozolomide response, whereas SLC17A7 tracks with neuronal differentiation and has been reported to oppose proliferative signaling, consistent with a sensitivity-associated role. Here, SLC17A7 is linked to glioblastoma.